Wednesday, July 8, 2026

Patent intelligence · US

US 8568713

Super fast-acting insulin compositions

granted A61KA61K38/28A61K38/47A61P
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 7
Applicant portfolio 70
Patent details — US 8568713
Jurisdiction
US
Status
granted
Grant date
Oct 29, 2013
Expiration
Oct 24, 2033
Applicant
HALOZYME, INC.
Claims
42
CPC classes
A61K, A61K38/28, A61K38/47, A61P
View on Google Patents ↗

Quick answer

US 8568713 (Super fast-acting insulin compositions) is held by HALOZYME, INC.. Status: granted. Granted Oct 29, 2013. Expires Oct 24, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
HALOZYME, INC.
Grant date
Expiration
Claims
42
CPC classes
A61K, A61K38/28, A61K38/47, A61P, A61P3/00, A61P3/10

More from HALOZYME, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12421308

    Anti-G-CSF antibodies and uses thereof

    ME Therapeutics Inc. · Expires Sep 18, 2045

    granted
  2. US 12371685

    PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof

    HALOZYME, INC. · Expires Jul 24, 2045

    granted
  3. US 12264345

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Mar 27, 2045

    granted
  4. US 12195773

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Jan 9, 2045

    granted
  5. US 12178860

    Hyaluronidase enzyme formulations for high volume administration

    HALOZYME, INC. · Expires Dec 26, 2044

    granted
  6. US 12152262

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Nov 21, 2044

    granted
  7. US 12123035

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Oct 17, 2044

    granted
  8. US 12110520

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Expires Oct 3, 2044

    granted

Frequently asked questions

What is US patent 8568713?

US 8568713 (Super fast-acting insulin compositions) is held by HALOZYME, INC.. Status: granted. Granted Oct 29, 2013. Expires Oct 24, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8568713?

HALOZYME, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 70 pharmaceutical patents for this assignee.

When does US 8568713 expire?

Our index shows an expiration date of Oct 24, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.